DEST Destiny Pharma Plc

TIDMDEST

Destiny Pharma PLC

02 July 2021

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Scientific Advisor Prof Dale Gerding to chair C. diff. Foundation Symposium

Brighton, United Kingdom - 02 July 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, is pleased to announce that its Scientific Advisory Board member, Professor Dale Gerding, a world-leading expert in C. difficile infections (CDI) and the discoverer of NTCD-M3, will be chairing the " C. diff . Patient, Family, and Caregiver" Symposium , to be held virtually on 16 July 2021.

The Symposium, hosted by the C Diff Foundation, will be a gathering of healthcare professionals, practitioners, thought leaders, and C. diff. survivors focused on transforming the patient experience of people living with C. diff. infections worldwide.

Distinguished members and keynote speakers will provide insight on how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.

Destiny Pharma's late-stage asset, NTCD-M3, is a novel microbiome therapeutic being developed to reduce the recurrence of C. diff infections in the gut. CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.

NTCD-M3 has the potential to become the leading treatment for CDI, as it has shown to deliver clear advantages to both existing CDI treatment options and also to those currently in clinical development.

Symposium registration is free of charge and is a live online event. Please register here .

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0) 1273 704 440

pressoffice@destinypharma.com

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Manel Mateus

+44 (0) 203 174 1789

destinypharma@optimumcomms.com

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

   For further information on the company, please visit   https://www.destinypharma.com 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUWCMUPGGAG

(END) Dow Jones Newswires

July 02, 2021 03:00 ET (07:00 GMT)

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024